The Food and Drug Administration (FDA) has approved Vykat™ XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome ...
Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of ...
The FDA Wednesday approved the first drug to treat people with Prader-Willi syndrome, a rare genetic disease that causes an ...
Pharmaceutical Technology on MSN10d
Soleno wins FDA approval for Prader-Willi hyperphagia treatmentSoleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...
Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...
Investor's Business Daily on MSN10d
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses LowerSoleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech ...
March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S.
The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic disorder, ...
Approval of Vykat XR marks the first treatment indicated for hyperphagia in patients with Prader-Willi syndrome.
Soleno Therapeutics' Vykat XR has become the first FDA-approved treatment for Prader-Willi syndrome (PWS), a rare genetic ...
Since 2000, when the FDA approved recombinant human growth hormone (rhGH) for those with the rare genetic disorder ...
Soleno Therapeutics (SLNO) stock skyrocketed up over 42% this past week on news that it has achieved a significant milestone with FDA approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback